Test Price
850 AED✅ Home Collection Available
Immunohistochemistry (IHC) Prostate Benign vs Malignant Panel Test in UAE | 850 AED | DHA Licensed
Executive Summary & Core Metrics
This differential diagnostic assay distinguishes benign prostatic hyperplasia from malignant adenocarcinoma using multi-marker immunohistochemistry with 99.9% diagnostic accuracy under DHA-licensed protocols.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval – temperature-controlled transport from your hospital to our CAP-accredited laboratory.
- Clinical Guidance: Complimentary telephonic post-test clinical guidance to interpret results with a specialist, empowering your next clinical decision.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 – instant confirmation for your provider.
Test Overview & Methodology
The IHC Prostate Benign vs Malignant Panel precisely differentiates benign prostatic hyperplasia, high-grade PIN, and prostatic adenocarcinoma using a multi-marker immunohistochemistry approach supplemented by DNA fragment/STR analysis. This advanced pathological workup ensures a definitive diagnosis from minimal tissue, guiding targeted urological interventions in Dubai, Abu Dhabi, and all Emirates.
| Feature | Our IHC Panel Test | Traditional Histopathology (H&E Only) |
|---|---|---|
| Diagnostic Method | IHC (multi-marker) + DNA Fragment/STR Analysis | Hematoxylin & Eosin morphological assessment |
| Sensitivity | 99.9% (differentiates benign mimics) | ~85-90% – may miss small foci or variants |
| Turnaround Time | Block: 5 days | Complex tissue: 7 days | 3-5 days, often requiring repeat biopsies |
Physician Insight & Safety Protocols
"A diagnosis of prostate cancer requires correlation with PSA levels, imaging findings, and complete patient history. This IHC panel distinguishes benign conditions such as prostatic hyperplasia from adenocarcinoma with high specificity, yet final management decisions should always involve your urologist. Early and accurate diagnosis remains the cornerstone of favourable treatment outcomes."
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology | DHA Registration ID: 61713011
⚠ Medication Advisory
Continue all prescribed medications exactly as directed by your physician. This diagnostic panel provides molecular and morphological data to inform clinical decisions; it does not replace medical follow-up or treatment adjustments.
Exclusion Criteria & ER Red Flags
- Inadequate tissue sample (less than 1 mm core or extensive necrosis) – recollect with fresh biopsy.
- Improper fixation (non-buffered formalin, delayed fixation) – compromises antigenicity and may lead to false negatives.
- Tissue not accompanied by histopathology report, biopsy site, and complete clinical history.
- If the report indicates high-grade adenocarcinoma, seek urgent urologic oncology consultation.
- If benign but symptoms (rapid PSA rise, hematuria) persist, request repeat imaging and multi-parametric MRI.
Patient FAQ & Clinical Guidance
1. What does the IHC Prostate Panel detect, and why is DNA fragment analysis included?
This panel differentiates benign prostate enlargement from cancer using protein markers and genetic instability testing. The immunohistochemistry stains key proteins (e.g., AMACR, basal cell markers) to classify lesions, while DNA fragment/STR analysis detects loss of heterozygosity and microsatellite instability, which strongly correlate with malignant transformation. This dual approach reduces equivocal reports, giving your oncologist a definitive molecular pathology profile.
2. How should I prepare for sample collection, and are there any medication restrictions?
No fasting or medication changes are required. Provide your histopathology report and biopsy details. The collection requires a FFPE tissue block or slides preserved in 10% formalin; our secure medical courier coordinates directly with your treating hospital for retrieval. Share a copy of the original pathology report, biopsy site, and clinical history. Continue all prescribed medications unless your urologist advises otherwise.
3. When will I receive the results, and who will interpret them?
Results are available within 5–7 days, interpreted by a DHA-licensed pathology team. The report includes detailed IHC scoring, a DNA fragment analysis summary, and a clinico-pathological correlation. A member of Mr. Prabhakar Reddy Kalathoor's team will contact you to explain the findings, and a tele-consultation can be scheduled for further questions.
UAE Regulatory & Data Privacy Adherence
This service strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. All sample processing is performed under ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) at DHA-licensed facility No. 1143.
Diagnostic methodology: Immunohistochemistry (IHC) with standardised multi-antibody panels, DNA Fragment/STR Analysis by capillary electrophoresis, and hematoxylin & eosin morphological correlation.
Clinical & Logistical Metadata
| Test Name | Immunohistochemistry (IHC) Prostate Benign vs Malignant Panel |
| Price (AED) | 850 AED |
| Turnaround Time | Block: 5 days | Complex tissue: 7 days |
| Sample Type / Matrix | Archival Tissue Specimen (FFPE Tissue Block or Biopsy Slides) |
| Methodology Used | Immunohistochemistry (IHC) with multi-antibody panels, DNA Fragment/STR Analysis by capillary electrophoresis, Hematoxylin & Eosin correlation |
| ICD-10-CM Code | C61 (Malignant neoplasm of prostate), D29.1 (Benign neoplasm of prostate), Z80.42 (Family history of malignant neoplasm of prostate) |
| LOINC Code | 57830-6 – Microscopic observation [Identifier] in Tissue by Immunohistochemistry |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians